MedPath

Effects of alpha-lipoic acid on patients undergoing hemodialysis

Phase 2
Completed
Conditions
Patient undergoing hemodialysis.
Chronic kidney disease, stage 5
N18.5
Registration Number
IRCT20160206026390N12
Lead Sponsor
Shahrekord University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
92
Inclusion Criteria

Patients (20-80 yr.) with a history of hemodialysis treatment for a minimum of six months
Willing to participate in the trial

Exclusion Criteria

-Any recent significant changes in patients' lifestyle behaviors (diet, physical activity, stress)
-History of consuming any antioxidant or anti-inflammatory dietary supplements less than one month before study enrollment
-Possible kidney transplantation
-History of alcohol consumption
-History of cigarette smoking
-Allergies or intolerance to alpha-lipoic acid
-History of cancer

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total Antioxidant Capacity. Timepoint: Before and after study. Method of measurement: Laboratory kits.;Tumor necrosis factor- alpha. Timepoint: Before and after study. Method of measurement: Laboratory kits.;Erythroblast Sedimentation Rate. Timepoint: Before and after study. Method of measurement: Laboratory kits.;Interleukin - 6. Timepoint: Before and after study. Method of measurement: Laboratory kits.;C-reactive Protein. Timepoint: Before and after study. Method of measurement: Laboratory kits.;Irisin. Timepoint: Before and after study. Method of measurement: Laboratory kits.
Secondary Outcome Measures
NameTimeMethod
Weight. Timepoint: Befor and after Study. Method of measurement: Sensitive Balance.
© Copyright 2025. All Rights Reserved by MedPath